Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 10/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 2/20 | 0.59 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6090471 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL15551092 | 0.98 | CYSLTR2 (0.97) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL15551091 | 0.98 | CYSLTR2 (0.97) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| SCHEMBL10402227 | 0.87 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| SCHEMBL10402225 | 0.87 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| SCHEMBL10402117 | 0.84 | CYSLTR2 (0.72) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| SCHEMBL10402118 | 0.84 | CYSLTR2 (0.72) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| SCHEMBL9757059 | 0.84 | CYSLTR1 (0.72) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| SCHEMBL9757052 | 0.84 | CYSLTR1 (0.72) | CYSLTR2CYSLTR1NPC1KDM4ELMNA | |
| SCHEMBL8107515 | 0.83 | CYSLTR2 (0.70) | CYSLTR2CYSLTR1NPC1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9095669-A | — | — | None | — | — | JP | disclosed |
| EP-3147280-B1 | ANTI-ANGIOGENIC COMPOUND | UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) | 2018-03-07 | — | — | EP | disclosed |
| US-9815788-B2 | Anti-angiogenic compounds | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2017-11-14 | — | — | US | disclosed |
| EP-3147280-A1 | ANTI-ANGIOGENIC COMPOUND | University College Dublin, National University of Ireland, Dublin (IE) | 2017-03-29 | — | — | EP | disclosed |
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-02-23 | — | — | US | disclosed |
| EP-2877454-B1 | ANTI-ANGIOGENIC 2-STYRYL-QUINOLINE COMPOUNDS | UNIV DUBLIN (IE) | 2016-11-02 | — | — | EP | disclosed |
| US-9388138-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-08-06 | — | — | US | disclosed |
| EP-2877454-A1 | ANTI-ANGIOGENIC COMPOUNDS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014012889-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2014-01-23 | — | — | WO | disclosed |
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| JP-H0995669-A | COMPOUND HAVING ULTRAVIOLET ABSORPTION CAPABLE OF CHANGING DEPENDING ON HYDROGEN ION CONCENTRATION | FUJI PHOTO FILM CO LTD | 1997-04-08 | — | — | JP | disclosed |
| US-4962203-A | ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROST CANADA, INC. (CA) | 1990-10-09 | — | — | US | disclosed |
| US-4918081-A | Quinoline derivatives and use thereof as antagonists of leukotriene d4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-17 | — | — | US | disclosed |
| WO-1989012629-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | CYSLTR2 1059/4885CYSLTR1 1915/4885NPC1 2305/4885 |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | CYSLTR2 1059/4885CYSLTR1 1915/4885NPC1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.